Rimegepant
As of the edition of 20 October 2026, Rimegepant is a small molecule: marketed, first approved in 2020 (US); acts on CALCRL; US protection ends in 2034.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2025
- Kind
- Small molecule
- Brand name
- Nurtec Odt
- First approved
- 27 February 2020 (US)
- Approvals on record
- 5 in 5 regions
- Holder of the most recent approval
- Pfizer; 2 holders in all
- Registered trials
- 46, 2 stopped early
- Disease areas
- Nervous system; Ear, nose and throat; Eye; Pregnancy and women's health; Urinary and reproductive; Cancer
US protection
US protection ends in 2034.
The last listed US drug-substance patent ends in 2034. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product3 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 3 listings behind itRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CALCRL | Calcitonin gene-related peptide type 1 receptor | Q16602 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 12 | 3 | 7 | 0 |
| Phase 1 | 2 | 0 | 2 | 0 |
| Phase 2 | 12 | 4 | 8 | 0 |
| Phase 3 | 13 | 8 | 4 | 1 |
| Phase 4 | 7 | 4 | 2 | 1 |
| All trials | 46 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant, Acquired holder and Lead sponsor of trials | 2021 to now |
| Biohaven Therapeutics | Originator | 2020 to 2023 |